Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Citigroup Q4 Earnings on the Deck: How to Approach the Stock Now?

View original at finance.yahoo.com
Citigroup Q4 Earnings on the Deck: How to Approach the Stock Now? Citigroup Inc. C is slated to report fourth-quarter and full-year 2025 results on Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Management expects NII (excluding Markets) to rise 5.5% on a year-over-year basis

    80% confidence
  • Citigroup expects market revenues to be down in the low to mid-single digit in the fourth quarter from a year ago

    80% confidence
  • Management expects IB fees to increase in the mid-20s (percentage) year over year in the fourth quarter

    80% confidence
  • Retail Services NCL is expected to be 5.75-6.25%

    80% confidence
  • Management anticipates expenses to be higher than $53.4 billion, including the impacts of FX translation and excluding the goodwill impairment

    80% confidence
  • The company is seeing continued momentum, particularly in M&A

    80% confidence
  • The efficiency ratio is expected to be slightly less than 64%

    80% confidence
  • Branded Cards net credit loss (NCL) is expected to be 3.50-4%

    80% confidence
  • The consensus estimate for earnings for the to-be-reported quarter has been revised downward to $1.65 over the past seven days, indicating a 23.1% rise from the prior-year quarter's actual

    80% confidence
  • Citigroup expects revenues to cross $84 billion compared with the prior mentioned $84.1 billion

    80% confidence
  • Its earnings outpaced the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 13.19%

    80% confidence
  • The Zacks Consensus Estimate for fourth-quarter sales is pegged at $20.94 billion, indicating a 6.9% year-over-year increase

    80% confidence
  • The transaction is expected to result in a pre-tax loss of $1.2 billion in the fourth quarter of 2025

    80% confidence

Data points we hold from this source

Citigroup Inc. · forward pe ratio11.92 ratio
Citigroup Inc. · non accrual loans3.7 billion_USD
Citigroup Inc. · principal transactions income2.1 billion_USD
Citigroup Inc. · efficiency ratio64 percent
Citigroup Inc. · revenue20.94 billion_USD
Citigroup Inc. · revenue84 billion_USD
Citigroup Inc. · average interest earning assets2.5 trillion_USD
Citigroup Inc. · commissions and fees2.9 billion_USD
Citigroup Inc. · market revenue4.5 billion_USD
Citigroup Inc. · net interest income14.9 billion_USD
Citigroup Inc. · non interest income5.9 billion_USD
Citigroup Inc. · administration and fiduciary fees1.0 billion_USD
Citigroup Inc. · stock repurchase authorization remaining11.3 billion_USD
Citigroup Inc. · dividend per share0.60 USD
Board of Governors of the Federal Reserve System · fed funds rate3.50-3.75 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Citigroup Q4 Earnings on the Deck: How to Approach the Stock Now? — Source | Via News | Finance Via News